CIAS
NTLA icon

Capital Investment Advisory Services’s Intellia Therapeutics NTLA Stock Holding History

Capital Investment Advisory Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,501
Closed -$254K – 862
2022
Q1 		$254K Sell
3,501
-534
-13% -$45.2K 0.03% 422
2021
Q4 		$477K Buy
+4,035
New +$505K 0.06% 281
2019
Q3 		– Sell
-600
Closed -$11K – 1436
2019
Q2 		$11K Buy
+600
New +$9.43K ﹤0.01% 952

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Investment Advisory Services's NTLA Position: Q2 2022 in Review

Capital Investment Advisory Services sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 3,501 shares — an estimated $254K sold.

Capital Investment Advisory Services first reported a position in NTLA in Q2 2019 and held it in 3 quarters. The position peaked at $477K in Q4 2021. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

  • Capital Investment Advisory Services reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Capital Investment Advisory Services sold 3,501 Intellia Therapeutics shares in Q2 2022, an estimated $254K.
  • Capital Investment Advisory Services first reported a position in Intellia Therapeutics in Q2 2019 and held it in 3 quarters.
  • Capital Investment Advisory Services's Intellia Therapeutics position peaked at $477K in Q4 2021.
  • 299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Capital Investment Advisory Services's 13F filing for Q2 2022, filed 22 Jul 2022.